EAM Investors’s Array Biopharma Inc ARRY Stock Holding History

EAM Investors’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-94,275	Closed	-$2.3M	–	340
2019 Q1	$2.3M	Buy	+94,275	New	+$1.96M	0.56%	49
2018 Q2	–	Sell	-177,747	Closed	-$2.9M	–	398
2018 Q1	$2.9M	Buy	177,747 +13,929	+9%	+$223K	0.48%	98
2017 Q4	$2.1M	Sell	163,818 -38,491	-19%	-$438K	0.38%	127
2017 Q3	$2.49M	Buy	+202,309	New	+$1.88M	0.33%	114
2017 Q1	–	Sell	-67,178	Closed	-$590K	–	409
2016 Q4	$590K	Sell	67,178 -78,504	-54%	-$578K	0.08%	296
2016 Q3	$983K	Buy	+145,682	New	+$563K	0.13%	252
2015 Q2	–	Sell	-149,121	Closed	-$1.1M	–	408
2015 Q1	$1.1M	Buy	+149,121	New	+$1.06M	0.13%	296

Other funds holding ARRY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM Investors's ARRY Position: Q2 2019 in Review

EAM Investors sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 94,275 shares — an estimated $2.3M sold.

EAM Investors first reported a position in ARRY in Q1 2015 and held it in 7 quarters. The position peaked at $2.9M in Q1 2018. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

EAM Investors reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
EAM Investors sold 94,275 Array Biopharma Inc shares in Q2 2019, an estimated $2.3M.
EAM Investors first reported a position in Array Biopharma Inc in Q1 2015 and held it in 7 quarters.
EAM Investors's Array Biopharma Inc position peaked at $2.9M in Q1 2018.
318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on EAM Investors's 13F filing for Q2 2019, filed 14 Aug 2019.